Symbiotec Pharmalab Limited

India Health

A leading specialist producer of steroid- hormone active pharmaceutical ingredients (APIs). These active ingredients are used by Symbiotec’s 200+ customers, which include both large multinationals as well as generic pharma companies, to manufacture high quality medications, including treatments for inflammation, asthma, dermatology, immune functions, and infertility

We are invested in Symbiotec Pharmalab Limited through Actis India 3 LP, which is managed by Actis LLP. For further information on the fund, the fund manager, and the expected impact of the fund’s investment, click here.

Key facts


Since 2012, we’ve only invested in Africa and South Asia. Investments outside these regions are from our pre-2012 portfolio.

South Asia

We have seven priority sectors. However, we continue to invest outside these sectors, largely in the most challenging regions, as new investment supporting any sector helps to underpin the private sector, and create jobs and livelihoods for people.

Investment type

We provide capital in three broad ways: direct equity, debt, and intermediated equity (principally through investment funds).

Intermediated investment
Actis India 3 LP
Fund Manager:
Actis LLP
Start date

For direct investments, this is the date CDC committed capital to the business or project.

For funds, this is the date that CDC committed capital to the fund.

For underlying fund investments, this is the date that the fund invested capital into the business.e

October 2013

This is the investee company’s place of incorporation; or a fund’s jurisdiction.